Keyword: Foundation Medicine
With new data exploring lung cancer biomarkers, Roche says that DNA blood tests could soon replace tissue biopsies for picking targeted treatments.
Foundation Medicine brought on Priti Hegde to be chief scientific officer and oversee its clinical product development and cancer genomics work.
Thrive debuted with $110 million, liquid biopsy technology from Johns Hopkins and Third Rock's Steve Kafka at the helm to catch cancer earlier.
Bayer teamed up with Foundation Medicine for diagnostic tests for several of its cancer therapies—starting with the tissue-agnostic Vitrakvi.
Roche’s VP of global oncology strategy, Cindy Perettie, will become the next CEO of Foundation Medicine, which it acquired last year for $2.4 billion.
BMS and Eisai spinoff H3 Biomedicine will conduct research aimed at developing immune therapies for cancer using the latter’s RNA-splicing platform.
Jason Ryan has hopped from Foundation to Medicine to Magenta Therapeutics after playing a key role in Foundation’s $2.4 billion buyout by Roche.
Novartis has tapped Foundation Medicine to develop companion diagnostic tests for its cancer treatment portfolio.
Roche and Foundation Medicine launched a blood test, analyzing 70 genes known to drive solid tumor growth, to guide precision cancer treatments.
Third Rock Ventures has named Steven Kafka, former president and chief operating officer of Foundation Medicine, as a new venture partner.